What’s the Optimal Tumor Model for Your Next Preclinical Immuno-Oncology Study?
Scientists at MI Bioresearch have run close to 1,000 preclinical immuno-oncology studies over the past five years. While new models continue to be developed, our scientists have found the following to be their commonly used “workhorse” models, time-tested and optimized for evaluating a wide range of therapeutic approaches.
The models discussed offer:
- Diverse histotypes for test agent development
- Data representing responsiveness to checkpoint inhibitors, costimulatory molecules, and/or focal radiation
- Corresponding links to posters and other data sources to aid in your decision-making process